Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
View original at globenewswire.comOnconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The pilot program at Salamanca City Central School District will expand to approximately 500 high school students in Fall 2026.
60% confidenceRealbotix's humanoid robots are manufactured in the United States using patented AI and robotics technologies enabling lifelike expressions, motion, vision, and social engagement.
60% confidenceOptio is designed to extend learning beyond school hours through personalized avatars trained in district curriculum, delivering educationally regulated support, concept reinforcement, individual tutoring, and 24/7 homework support across multiple languages.
60% confidenceThe combined company is expected to trade on Nasdaq following closing of the acquisition, which is anticipated to occur in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.
60% confidenceThe Optio platform includes education-specific safety guardrails, protections against inappropriate responses, and operates under full district oversight.
60% confidenceThe Realbotix M-Series humanoid robot uses natural conversation, facial expressions, and real-time interaction to create hands-on learning experiences in the classroom.
60% confidenceOptio is designed to support neurodiverse learners through personalized, always-available reinforcement.
60% confidenceOnconetix owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp.
60% confidence